CoChat
Sign Up
Cited by 110Congenital heart defects researchCardiac Fibrosis and RemodelingAngiogenesis and VEGF in Cancer

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Nogo-B promotes angiogenesis and improves cardiac repair after myocardial infarction via activating Notch1 signaling

Open access
Zheng, Yanjun, Lin, Jingrong, Liu, Dingsheng, Wan, Guoqing, Gu, Xuefeng, Ma, Jian·2022·Cell Death & Disease
DOI 10.1038/s41419-022-04754-4PMC PMC8983727
Open this paper in CoChat — free accountOpen PDF

Abstract

Nogo-B (Reticulon 4B) is reportedly a regulator of angiogenesis during the development and progression of cancer. However, whether Nogo-B regulates angiogenesis and post-myocardial infarction (MI) cardiac repair remains elusive. In the present study, we aimed to explore the role and underlying mechanisms of Nogo-B in cardiac repair during MI. We observed an increased expression level of Nogo-B in the heart of mouse MI models, as well as in isolated cardiac microvascular endothelial cells (CMECs). Moreover, Nogo-B was significantly upregulated in CMECs exposed to oxygen-glucose deprivation (OGD). Nogo-B overexpression in the endothelium via cardiotropic adeno-associated virus serotype 9 (AAV9) with the mouse endothelial-specific promoter Tie2 improved heart function, reduced scar size, and increased angiogenesis. RNA-seq data indicated that Notch signaling is a deregulated pathway in isolated CMECs along the border zone of the infarct with Nogo-B overexpression. Mechanistically, Nogo-B activated Notch1 signaling and upregulated Hes1 in the MI hearts. Inhibition of Notch signaling using a specific siRNA and γ-secretase inhibitor abolished the promotive effects of Nogo-B overexpression on network formation and migration of isolated cardiac microvascular endothelial cells (CMECs). Furthermore, endothelial Notch1 heterozygous deletion inhibited Nogo-B-induced cardioprotection and angiogenesis in the MI model. Collectively, this study demonstrates that Nogo-B is a positive regulator of angiogenesis by activating the Notch signaling pathway, suggesting that Nogo-B is a novel molecular target for ischemic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-022-04754-4

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Nogo-B was increased in CMECs after MI. A, B Time course of the relative mRNA level of Nogo-B measured by Q-PCR in cardiac tissues and CMECs in the infarct border zone after MI (n = 5). C Representative and quantitative Nogo-B protein level in CMECs in the infarct border zone after MI (n = 5). D Representative and quantitative analysis of scratch, transwell, and tube formation images under normoxic or OGD conditions (n = 5). E, F mRNA and protein levels of Nogo-B after normoxic or OGD treatment (n = 5). Data were expressed as mean ± SEM. ∗P < 0.05 versus sham or normoxic group. Unpaired Student’s t-test (D–F), one-way ANOVA (A–C).
Fig. 1 Nogo-B was increased in CMECs after MI. A, B Time course of the relative mRNA level of Nogo-B measured by Q-PCR in cardiac tissues and CMECs in the infarct border zone after MI (n = 5). C Representative and quantitative Nogo-B protein level in CMECs in the infarct border zone after MI (n = 5). D Representative and quantitative analysis of scratch, transwell, and tube formation images under normoxic or OGD conditions (n = 5). E, F mRNA and protein levels of Nogo-B after normoxic or OGD treatment (n = 5). Data were expressed as mean ± SEM. ∗P < 0.05 versus sham or normoxic group. Unpaired Student’s t-test (D–F), one-way ANOVA (A–C).CC BY · PubMed Central
Fig. 2 Nogo-B treatment improved cardiac functions. A The survival rate of sham and MI mice injected with AAV during the 4-week follow-up period. The log-rank test demonstrated significant differences between the two survival curves. B LVEF, LVFS, LVEDD, and LVEDS were measured by echocardiography (n = 8). C LVDP, LVEDP, LV maximum ascending rates of pressure (+dp/dt max), and LVESV measured by the pressure–volume loop at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. #P < 0.05, ##P < 0.01, ###P < 0.001 versus AAV-NC-MI group. two-way ANOVA (B, C).
Fig. 2 Nogo-B treatment improved cardiac functions. A The survival rate of sham and MI mice injected with AAV during the 4-week follow-up period. The log-rank test demonstrated significant differences between the two survival curves. B LVEF, LVFS, LVEDD, and LVEDS were measured by echocardiography (n = 8). C LVDP, LVEDP, LV maximum ascending rates of pressure (+dp/dt max), and LVESV measured by the pressure–volume loop at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. #P < 0.05, ##P < 0.01, ###P < 0.001 versus AAV-NC-MI group. two-way ANOVA (B, C).CC BY · PubMed Central
Fig. 3 Nogo-B decreased fibrosis and increased angiogenesis after MI. A The heart weight to body weight ratio (n = 8). B Representative cross-sectional images and quantitative data of hearts stained with Masson’s trichrome at day 28 post-MI (n = 5). C Representation and quantification of IHC staining for TUNEL + cardiomyocytes in the border zone of infarcted hearts at day 3 post-MI (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. #P < 0.05, ##P < 0.01, ###P < 0.001 versus AAV-NC-MI group. D The viability of NRCMs was measured by the Cell Counting Kit-8 (CCK8) in the medium (n = 3). E Fold changes of LDH activities in the NRCMs medium. *P < 0.05 versus Ad-NC group (n = 3). #P < 0.05, ##P < 0.01 versus Ad-NC-OGD group. Data were expressed as mean ± SEM. Unpaired Student’s t-test (B), two-way ANOVA (A and C–E).
Fig. 3 Nogo-B decreased fibrosis and increased angiogenesis after MI. A The heart weight to body weight ratio (n = 8). B Representative cross-sectional images and quantitative data of hearts stained with Masson’s trichrome at day 28 post-MI (n = 5). C Representation and quantification of IHC staining for TUNEL + cardiomyocytes in the border zone of infarcted hearts at day 3 post-MI (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. #P < 0.05, ##P < 0.01, ###P < 0.001 versus AAV-NC-MI group. D The viability of NRCMs was measured by the Cell Counting Kit-8 (CCK8) in the medium (n = 3). E Fold changes of LDH activities in the NRCMs medium. *P < 0.05 versus Ad-NC group (n = 3). #P < 0.05, ##P < 0.01 versus Ad-NC-OGD group. Data were expressed as mean ± SEM. Unpaired Student’s t-test (B), two-way ANOVA (A and C–E).CC BY · PubMed Central
Fig. 4 Nogo-B promoted angiogenesis after MI. A The mRNA level of VEGF at day 28 post-MI (n = 5). B The protein level of VEGF at day 28 post-MI in border (BZ) and remote zone (RZ) of infarcted hearts. C Immunochemistry staining for CD31 + endothelial cells and α-SMA + vessels at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. two-way ANOVA (A–C).
Fig. 4 Nogo-B promoted angiogenesis after MI. A The mRNA level of VEGF at day 28 post-MI (n = 5). B The protein level of VEGF at day 28 post-MI in border (BZ) and remote zone (RZ) of infarcted hearts. C Immunochemistry staining for CD31 + endothelial cells and α-SMA + vessels at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus AAV-NC group. two-way ANOVA (A–C).CC BY · PubMed Central
Fig. 5 Nogo-B promoted angiogenesis in vitro. A The expression efficiency of Ad-Nogo-B measured by Western blot (n = 4). B The downregulation efficiency of Ad-siNogo-B measured by Western blot (n = 4). C Transwell and scratch/wound assays and tube formation analysis demonstrated that Nogo-B promoted cellular migration of ECs (n = 5). D Effect of Ad-Nogo-B and Ad-shNogo-B on vessel outgrowth in aortic rings and ECs tube formation (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus Ad-NC group. #P < 0.05, ##P < 0.01 versus Ad-Scr group. one-way ANOVA (C, D).
Fig. 5 Nogo-B promoted angiogenesis in vitro. A The expression efficiency of Ad-Nogo-B measured by Western blot (n = 4). B The downregulation efficiency of Ad-siNogo-B measured by Western blot (n = 4). C Transwell and scratch/wound assays and tube formation analysis demonstrated that Nogo-B promoted cellular migration of ECs (n = 5). D Effect of Ad-Nogo-B and Ad-shNogo-B on vessel outgrowth in aortic rings and ECs tube formation (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus Ad-NC group. #P < 0.05, ##P < 0.01 versus Ad-Scr group. one-way ANOVA (C, D).CC BY · PubMed Central
Fig. 6 Nogo-B overexpression upregulated the Notch signaling pathway. A Heat map of genes related to the Notch pathway with RNA-seq for CMECs from AAV-NC or AAV-Nogo-B-infected mice after MI. B GSEA analyses of the gene set upregulated by Nogo-B overexpression in CMECs. C Protein levels of Notch and Hes1 in the AAV-Nogo-B and AAV-NC infected hearts after MI in border (BZ) and remote zone (RZ) of infarcted hearts (n = 5). *P < 0.05, **P < 0.01 versus sham group. D Protein levels of Notch and Hes1 in ECs treated with DAPT and siNotch (n = 5). *P < 0.05, **P < 0.01 versus Ad-NC group. ns, not significant. Data were expressed as mean ± SEM. Two-way ANOVA (C, D).
Fig. 6 Nogo-B overexpression upregulated the Notch signaling pathway. A Heat map of genes related to the Notch pathway with RNA-seq for CMECs from AAV-NC or AAV-Nogo-B-infected mice after MI. B GSEA analyses of the gene set upregulated by Nogo-B overexpression in CMECs. C Protein levels of Notch and Hes1 in the AAV-Nogo-B and AAV-NC infected hearts after MI in border (BZ) and remote zone (RZ) of infarcted hearts (n = 5). *P < 0.05, **P < 0.01 versus sham group. D Protein levels of Notch and Hes1 in ECs treated with DAPT and siNotch (n = 5). *P < 0.05, **P < 0.01 versus Ad-NC group. ns, not significant. Data were expressed as mean ± SEM. Two-way ANOVA (C, D).CC BY · PubMed Central
Fig. 7 Notch pathway inhibition abolished Nogo-B overexpression in ECs network formation and migration. A DAPT treatment on migration, invasion, and tube formation in Ad-NC and Ad-Nogo-B-infected ECs (n = 5). B DAPT treatment on the effect of Ad-Nogo-B and Ad-NC on vessel outgrowth in aortic rings and ECs tube formation (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01 versus Ad-NC group. #P < 0.05, ##P < 0.01 versus Ad-Nogo-B group. two-way ANOVA (A, B).
Fig. 7 Notch pathway inhibition abolished Nogo-B overexpression in ECs network formation and migration. A DAPT treatment on migration, invasion, and tube formation in Ad-NC and Ad-Nogo-B-infected ECs (n = 5). B DAPT treatment on the effect of Ad-Nogo-B and Ad-NC on vessel outgrowth in aortic rings and ECs tube formation (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01 versus Ad-NC group. #P < 0.05, ##P < 0.01 versus Ad-Nogo-B group. two-way ANOVA (A, B).CC BY · PubMed Central
Fig. 8 Notch pathway inhibition abolished the cardioprotective effect of Nogo-B in MI-injured hearts. A The vessel outgrowth in aortic rings of Nogo-B overexpressed and endothelial cell-specific Notch1 heterozygous (Notch1-EC+/−) mice or littermates (n = 3). *P < 0.05 versus Ad-NC group. #P < 0.05 versus Ad-Nogo-B group. B The survival rate of Notch1-EC+/− and Ctrl mice injected with AAV-Nogo-B and AAV-NC after MI. The log-rank test demonstrated significant differences between the two survival curves. C LVEF and LVFS were measured by echocardiography (n = 5). D Quantitative data of hearts stained with Masson’s trichrome at day 28 post-MI (n = 5). E Representation and quantification of IHC staining for TUNEL + cardiomyocytes in the border zone of infarcted hearts at day 3 post-MI (n = 3). F Immunochemistry staining for CD31 + endothelial cells and α-SMA + vessels at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01 versus AAV-NC group. #P < 0.05, ##P < 0.01 versus AAV-Nogo-B group. two-way ANOVA (A and C–F).
Fig. 8 Notch pathway inhibition abolished the cardioprotective effect of Nogo-B in MI-injured hearts. A The vessel outgrowth in aortic rings of Nogo-B overexpressed and endothelial cell-specific Notch1 heterozygous (Notch1-EC+/−) mice or littermates (n = 3). *P < 0.05 versus Ad-NC group. #P < 0.05 versus Ad-Nogo-B group. B The survival rate of Notch1-EC+/− and Ctrl mice injected with AAV-Nogo-B and AAV-NC after MI. The log-rank test demonstrated significant differences between the two survival curves. C LVEF and LVFS were measured by echocardiography (n = 5). D Quantitative data of hearts stained with Masson’s trichrome at day 28 post-MI (n = 5). E Representation and quantification of IHC staining for TUNEL + cardiomyocytes in the border zone of infarcted hearts at day 3 post-MI (n = 3). F Immunochemistry staining for CD31 + endothelial cells and α-SMA + vessels at day 28 post-MI (n = 5). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01 versus AAV-NC group. #P < 0.05, ##P < 0.01 versus AAV-Nogo-B group. two-way ANOVA (A and C–F).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 110

Related

See all

Metadata

Authors
Zheng, Y., Lin, J., Liu, D., Wan, G., Gu, X., & Ma, J.
Affiliations
  • Shanghai University of Medicine and Health Sciences (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
Ma, Jian
ORCID
Venue
Cell Death & Disease
Publisher
Springer Science and Business Media LLC
Published
2022-04-05
Volume
13
Issue
4
Pages
306-306
ISSN
2041-4889 (ISSN-L)
DOI
10.1038/s41419-022-04754-4
PMC
PMC8983727
OpenAlex
W4224325360
Cited by
110
References
52
Citations by year
2026: 20 · 2025: 53 · 2024: 21 · 2023: 14 · 2022: 1
FWCI
7.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Shanghai Key Laboratory of Molecular Imaging (18DZ2260400, 81970229, 81700354)
  • Ruijin Hospital
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
Nogo-B, angiogenesis, myocardial infarction, cardiac repair, Notch1 signaling, Hes1, cardiac microvascular endothelial cells, oxygen-glucose deprivation, gamma-secretase inhibition, AAV9 gene delivery, ischemic heart disease, endothelial cell migration
MeSH terms
Animals, Endothelium, Myocardial Infarction, Neovascularization, Pathologic, Signal Transduction, Endothelial Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review